ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's Disease
Identifieur interne : 001B52 ( PascalFrancis/Curation ); précédent : 001B51; suivant : 001B53ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's Disease
Auteurs : O. Rascol [France] ; O. Blin [France] ; C. Thalamas [France] ; S. Descombes [France] ; C. Soubrouillard [France] ; P. Azulay [France] ; N. Fabre [France] ; F. Viallet [France] ; K. Lafnitzegger [États-Unis] ; S. Wright [États-Unis] ; J. H. Carter [États-Unis] ; J. G. Nutt [États-Unis]Source :
- Annals of neurology [ 0364-5134 ] ; 1999.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Studies in animal models show a selective D1 receptor agonist with full functional efficacy compared with dopamine to have antiparkinsonian efficacy of similar magnitude to levodopa, without the same propensity for inducing dyskinesia. To date, no such agent has been tested in humans. ABT-431 is the prodrug of A-86929, a full, selective D1 receptor agonist. Subjects (n = 14) with levodopa-responsive Parkinson's disease received five doses of ABT-431 (5, 10, 20, 30, and 40 mg) and one of placebo after a 12-hour levodopa holiday. Response was assessed by using the Unified Parkinson's Disease Rating Scale motor subsection. Dyskinesia was separately graded. ABT-431 showed efficacy significantly superior to placebo at doses of 10 mg and more, and of similar magnitude to that seen with levodopa. Dyskinesia was reduced in several patients after receiving ABT-431. There were no serious adverse events, the most common minor events being nausea and emesis, dizziness, and hypotension. Assuming that ABT-431 is not transformed in humans into an unknown active D2 metabolite, and remains selective for D1 receptors, it is the first dopamine D1 receptor agonist to demonstrate a full antiparkinsonian effect in patients with Parkinson's disease. These preliminary findings also suggest that it may exhibit a reduced tendency to provoke dyskinesia. The emergence of a well-tolerated D1 agonist should allow for the development of a better understanding of the relation between motor efficacy and dyskinesia in Parkinson's disease.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001493
Links to Exploration step
Pascal:99-0342238Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's Disease</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Pharmacology and Neurology, INSERM U455, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre de Pharmacologie Clinique et d'Evaluations Therapeutiques (CPCET), Department of Neurology</s1><s2>Marseille</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Pharmacology and Neurology, INSERM U455, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Descombes, S" sort="Descombes, S" uniqKey="Descombes S" first="S." last="Descombes">S. Descombes</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Pharmacology and Neurology, INSERM U455, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Soubrouillard, C" sort="Soubrouillard, C" uniqKey="Soubrouillard C" first="C." last="Soubrouillard">C. Soubrouillard</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre de Pharmacologie Clinique et d'Evaluations Therapeutiques (CPCET), Department of Neurology</s1><s2>Marseille</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Azulay, P" sort="Azulay, P" uniqKey="Azulay P" first="P." last="Azulay">P. Azulay</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre de Pharmacologie Clinique et d'Evaluations Therapeutiques (CPCET), Department of Neurology</s1><s2>Marseille</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Pharmacology and Neurology, INSERM U455, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F." last="Viallet">F. Viallet</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology</s1><s2>Aix-en-Provence</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Lafnitzegger, K" sort="Lafnitzegger, K" uniqKey="Lafnitzegger K" first="K." last="Lafnitzegger">K. Lafnitzegger</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Neuroscience Venture, Abbott Laboratories</s1><s2>Abbott Park, IL</s2><s3>USA</s3><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Wright, S" sort="Wright, S" uniqKey="Wright S" first="S." last="Wright">S. Wright</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Neuroscience Venture, Abbott Laboratories</s1><s2>Abbott Park, IL</s2><s3>USA</s3><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Carter, J H" sort="Carter, J H" uniqKey="Carter J" first="J. H." last="Carter">J. H. Carter</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Oregon Health Sciences University</s1><s2>Portland, OR</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Nutt, J G" sort="Nutt, J G" uniqKey="Nutt J" first="J. G." last="Nutt">J. G. Nutt</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Oregon Health Sciences University</s1><s2>Portland, OR</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">99-0342238</idno><date when="1999">1999</date><idno type="stanalyst">PASCAL 99-0342238 INIST</idno><idno type="RBID">Pascal:99-0342238</idno><idno type="wicri:Area/PascalFrancis/Corpus">001493</idno><idno type="wicri:Area/PascalFrancis/Curation">001B52</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's Disease</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Pharmacology and Neurology, INSERM U455, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre de Pharmacologie Clinique et d'Evaluations Therapeutiques (CPCET), Department of Neurology</s1><s2>Marseille</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Pharmacology and Neurology, INSERM U455, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Descombes, S" sort="Descombes, S" uniqKey="Descombes S" first="S." last="Descombes">S. Descombes</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Pharmacology and Neurology, INSERM U455, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Soubrouillard, C" sort="Soubrouillard, C" uniqKey="Soubrouillard C" first="C." last="Soubrouillard">C. Soubrouillard</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre de Pharmacologie Clinique et d'Evaluations Therapeutiques (CPCET), Department of Neurology</s1><s2>Marseille</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Azulay, P" sort="Azulay, P" uniqKey="Azulay P" first="P." last="Azulay">P. Azulay</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre de Pharmacologie Clinique et d'Evaluations Therapeutiques (CPCET), Department of Neurology</s1><s2>Marseille</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Pharmacology and Neurology, INSERM U455, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F." last="Viallet">F. Viallet</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology</s1><s2>Aix-en-Provence</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Lafnitzegger, K" sort="Lafnitzegger, K" uniqKey="Lafnitzegger K" first="K." last="Lafnitzegger">K. Lafnitzegger</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Neuroscience Venture, Abbott Laboratories</s1><s2>Abbott Park, IL</s2><s3>USA</s3><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Wright, S" sort="Wright, S" uniqKey="Wright S" first="S." last="Wright">S. Wright</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Neuroscience Venture, Abbott Laboratories</s1><s2>Abbott Park, IL</s2><s3>USA</s3><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Carter, J H" sort="Carter, J H" uniqKey="Carter J" first="J. H." last="Carter">J. H. Carter</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Oregon Health Sciences University</s1><s2>Portland, OR</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Nutt, J G" sort="Nutt, J G" uniqKey="Nutt J" first="J. G." last="Nutt">J. G. Nutt</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Oregon Health Sciences University</s1><s2>Portland, OR</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></analytic><series><title level="j" type="main">Annals of neurology</title><title level="j" type="abbreviated">Ann. neurol.</title><idno type="ISSN">0364-5134</idno><imprint><date when="1999">1999</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Annals of neurology</title><title level="j" type="abbreviated">Ann. neurol.</title><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term><term>Antiparkinson agent</term><term>Chemotherapy</term><term>D1 Dopamine receptor</term><term>Human</term><term>Parkinson disease</term><term>Previous study</term><term>Prodrug</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term><term>Agoniste</term><term>Récepteur dopaminergique D1</term><term>Etude préalable</term><term>Traitement</term><term>Homme</term><term>Chimiothérapie</term><term>Antiparkinsonien</term><term>Promédicament</term><term>ABT-431</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Studies in animal models show a selective D1 receptor agonist with full functional efficacy compared with dopamine to have antiparkinsonian efficacy of similar magnitude to levodopa, without the same propensity for inducing dyskinesia. To date, no such agent has been tested in humans. ABT-431 is the prodrug of A-86929, a full, selective D1 receptor agonist. Subjects (n = 14) with levodopa-responsive Parkinson's disease received five doses of ABT-431 (5, 10, 20, 30, and 40 mg) and one of placebo after a 12-hour levodopa holiday. Response was assessed by using the Unified Parkinson's Disease Rating Scale motor subsection. Dyskinesia was separately graded. ABT-431 showed efficacy significantly superior to placebo at doses of 10 mg and more, and of similar magnitude to that seen with levodopa. Dyskinesia was reduced in several patients after receiving ABT-431. There were no serious adverse events, the most common minor events being nausea and emesis, dizziness, and hypotension. Assuming that ABT-431 is not transformed in humans into an unknown active D2 metabolite, and remains selective for D1 receptors, it is the first dopamine D1 receptor agonist to demonstrate a full antiparkinsonian effect in patients with Parkinson's disease. These preliminary findings also suggest that it may exhibit a reduced tendency to provoke dyskinesia. The emergence of a well-tolerated D1 agonist should allow for the development of a better understanding of the relation between motor efficacy and dyskinesia in Parkinson's disease.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0364-5134</s0></fA01><fA02 i1="01"><s0>ANNED3</s0></fA02><fA03 i2="1"><s0>Ann. neurol.</s0></fA03><fA05><s2>45</s2></fA05><fA06><s2>6</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's Disease</s1></fA08><fA11 i1="01" i2="1"><s1>RASCOL (O.)</s1></fA11><fA11 i1="02" i2="1"><s1>BLIN (O.)</s1></fA11><fA11 i1="03" i2="1"><s1>THALAMAS (C.)</s1></fA11><fA11 i1="04" i2="1"><s1>DESCOMBES (S.)</s1></fA11><fA11 i1="05" i2="1"><s1>SOUBROUILLARD (C.)</s1></fA11><fA11 i1="06" i2="1"><s1>AZULAY (P.)</s1></fA11><fA11 i1="07" i2="1"><s1>FABRE (N.)</s1></fA11><fA11 i1="08" i2="1"><s1>VIALLET (F.)</s1></fA11><fA11 i1="09" i2="1"><s1>LAFNITZEGGER (K.)</s1></fA11><fA11 i1="10" i2="1"><s1>WRIGHT (S.)</s1></fA11><fA11 i1="11" i2="1"><s1>CARTER (J. H.)</s1></fA11><fA11 i1="12" i2="1"><s1>NUTT (J. G.)</s1></fA11><fA14 i1="01"><s1>Clinical Investigation Centre, Departments of Pharmacology and Neurology, INSERM U455, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="02"><s1>Centre de Pharmacologie Clinique et d'Evaluations Therapeutiques (CPCET), Department of Neurology</s1><s2>Marseille</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Neurology</s1><s2>Aix-en-Provence</s2><s3>FRA</s3><sZ>8 aut.</sZ></fA14><fA14 i1="04"><s1>Neuroscience Venture, Abbott Laboratories</s1><s2>Abbott Park, IL</s2><s3>USA</s3><sZ>9 aut.</sZ><sZ>10 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Neurology, Oregon Health Sciences University</s1><s2>Portland, OR</s2><s3>USA</s3><sZ>11 aut.</sZ><sZ>12 aut.</sZ></fA14><fA20><s1>736-741</s1></fA20><fA21><s1>1999</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>16555</s2><s5>354000084807420070</s5></fA43><fA44><s0>0000</s0><s1>© 1999 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>25 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>99-0342238</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Annals of neurology</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Studies in animal models show a selective D1 receptor agonist with full functional efficacy compared with dopamine to have antiparkinsonian efficacy of similar magnitude to levodopa, without the same propensity for inducing dyskinesia. To date, no such agent has been tested in humans. ABT-431 is the prodrug of A-86929, a full, selective D1 receptor agonist. Subjects (n = 14) with levodopa-responsive Parkinson's disease received five doses of ABT-431 (5, 10, 20, 30, and 40 mg) and one of placebo after a 12-hour levodopa holiday. Response was assessed by using the Unified Parkinson's Disease Rating Scale motor subsection. Dyskinesia was separately graded. ABT-431 showed efficacy significantly superior to placebo at doses of 10 mg and more, and of similar magnitude to that seen with levodopa. Dyskinesia was reduced in several patients after receiving ABT-431. There were no serious adverse events, the most common minor events being nausea and emesis, dizziness, and hypotension. Assuming that ABT-431 is not transformed in humans into an unknown active D2 metabolite, and remains selective for D1 receptors, it is the first dopamine D1 receptor agonist to demonstrate a full antiparkinsonian effect in patients with Parkinson's disease. These preliminary findings also suggest that it may exhibit a reduced tendency to provoke dyskinesia. The emergence of a well-tolerated D1 agonist should allow for the development of a better understanding of the relation between motor efficacy and dyskinesia in Parkinson's disease.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02B06</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Agoniste</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Agonist</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Agonista</s0><s5>04</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Récepteur dopaminergique D1</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>D1 Dopamine receptor</s0><s5>05</s5><s6>«D1» Dopamine receptor</s6></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Receptor dopaminérgico D1</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Etude préalable</s0><s5>16</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Previous study</s0><s5>16</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Estudio previo</s0><s5>16</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0><s5>17</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0><s5>17</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0><s5>17</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0><s5>20</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Human</s0><s5>20</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0><s5>20</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0><s5>23</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0><s5>23</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0><s5>23</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Antiparkinsonien</s0><s5>24</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Antiparkinson agent</s0><s5>24</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Antiparkinsoniano</s0><s5>24</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Promédicament</s0><s5>35</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Prodrug</s0><s5>35</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Promedicamento</s0><s5>35</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>ABT-431</s0><s2>FR</s2><s4>INC</s4><s5>86</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>41</s5></fC07><fN21><s1>214</s1></fN21></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B52 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001B52 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:99-0342238
|texte= ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.29. |  |